Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study
Clinical trial NCT05071703 · COMPLETED
Trial details
- NCT number
- NCT05071703
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-11
- Primary completion
- 2022-04-10
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.